Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 5Completed 3Not yet recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 115Carcinoma, Non-Small-Cell Lung 103Prostatic Neoplasms 90Neoplasms 74Multiple Myeloma 73Lung Neoplasms 64Colorectal Neoplasms 50Leukemia, Myeloid, Acute 46Neoplasm Metastasis 43Lymphoma 39Pancreatic Neoplasms 38Melanoma 38Lymphoma, Non-Hodgkin 36Carcinoma, Renal Cell 36Ovarian Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Squamous Cell Carcinoma of Head and Neck 31Urinary Bladder Neoplasms 30Hematologic Neoplasms 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Endometrial Neoplasms 26Uterine Cervical Neoplasms 25Carcinoma, Hepatocellular 25Triple Negative Breast Neoplasms 24Sarcoma 24Glioma 24Stomach Neoplasms 22Head and Neck Neoplasms 22Lymphoma, Large B-Cell, Diffuse 21Brain Neoplasms 21

Interventions

venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Dexamethasone 1Calcium Dobesilate 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Immunoglobulin Light-chain Amyloidosis × 30 days × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05951049 2026-05-06

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Attralus, Inc.

Phase 2 Active not recruiting
120 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡